Focus on Mitral Valve InterventionsNYHA Functional Classification and Outcomes After Transcatheter Mitral Valve Repair in Heart Failure: The COAPT Trial
Central Illustration
Key Words
Abbreviations and Acronyms
Cited by (0)
The COAPT trial was sponsored by Abbott. Dr. Giustino has received consulting fees (advisory board) from Bristol Myers Squibb/Pfizer. Dr. Lindenfeld has received research grant support from AstraZeneca; and has received consulting income from Abbott Vascular, AstraZeneca, CVRx, Edwards Lifesciences, Impulse Dynamics, Boehringer Ingelheim, and V-Wave. Dr. Abraham has received research grant support from Abbott Vascular; and has received consulting income from Abbott Vascular. Dr. Kar has received consulting fees from and is an advisory board member for Boston Scientific; has received consulting fees from and holds stock equity in Valcare; and has received consulting fees from W.L. Gore and Medtronic. Dr. Lim has received research grant support from Abbott, Edwards Lifesciences, Medtronic, and W.L. Gore; is a consultant for Abbott, Edwards Lifesciences, Keystone Heart, Pipeline, Siemens, Valgen, and Venus; is an advisory board member for Ancora and Venus; and holds equity in 510 Kardiac Devices and Venus. Dr. Grayburn has received consulting fees from Abbott Vascular, Edwards Lifesciences, W.L. Gore, Medtronic, and 4C Medical; and has received grant support from Abbott Vascular, Boston Scientific, Cardiovalve, Edwards Lifesciences, W.L. Gore, Medtronic, and NeoChord. Dr. Kapadia holds stock options in Navigate Cardiac Structures. Dr. Cohen has received research grant support from Abbott, Medtronic, Edwards Lifesciences, and Boston Scientific; and has received consulting income from Abbott, Medtronic, Edwards Lifesciences, and Boston Scientific. Dr. Weissman is associate director of an academic echocardiography core laboratory (MedStar Health Research Institute) with institutional contracts with Abbott, Neovasc, Ancora, Mitralign, Medtronic, Boston Scientific, Edwards Lifesciences, Biotronik, and LivaNova. Dr. Mack served as co–primary investigator for the PARTNER trial for Edwards Lifesciences and the COAPT trial for Abbott; and served as study chair for the APOLLO trial for Medtronic. Dr. Stone has received speaking or other honoraria from Cook, Terumo, Qool Therapeutics, and Orchestra Biomed; is a consultant to Valfix, TherOx, Vascular Dynamics, Robocath, HeartFlow, W.L. Gore, Ablative Solutions, Miracor, Neovasc, V-Wave, Abiomed, Ancora, MAIA Pharmaceuticals, Vectorious, Reva, Matrizyme, CardioMech; holds equity or options in Ancora, Qool Therapeutics, Cagent, Applied Therapeutics, the Biostar family of funds, SpectraWave, Orchestra Biomed, Aria, Cardiac Success, the MedFocus family of funds, and Valfix; and is principal investigator for the COAPT trial (uncompensated). Dr. Kotinkaduwa has reported that she has no relationships relevant to the contents of this paper to disclose.
The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the JACC: Cardiovascular Interventions author instructions page.